GMR Solutions adds two healthcare executives to its board

GMR Solutions, Inc. (NYSE: GMRS) announced the appointments of Dr. Amar Desai and Ellen Zane to its Board of Directors, effective July 1, 2026, according to a press release from the company.

Dr. Desai most recently served as President of Optum Integrated Care and previously as Chief Executive Officer of Optum Health at UnitedHealth Group, where he oversaw care delivery for more than 20 million patients. He has also held senior roles at CVS Health, DaVita, USC Care, and McKinsey & Company. Dr. Desai will serve on the Board's Nominating, Corporate Governance and Compliance Committee.

Zane is CEO Emeritus of Tufts Medical Center and Founding Chair of Tufts Medicine. She currently serves on the boards of Boston Scientific, Haemonetics Corporation, and Synchrony Financial, and holds an adjunct faculty position at Harvard T.H. Chan School of Public Health. Zane will chair the Board's Human Capital and Compensation Committee.

"The completion of our Board marks an important milestone for GMR as a public company," said GMR Chief Executive Officer and Chairman Nick Loporcaro. "Our directors bring diverse perspectives and deep expertise from organizations that have transformed healthcare delivery, improved patient access and driven operational excellence at scale."

The full board now includes Timothy Wicks, former Chief Financial Officer of Optum; Jan Stern Reed, former Senior Vice President and General Counsel of Walgreens Boots Alliance; Johnny Kim, Managing Director on KKR's Health Care industry team; Max Lin, Partner and Head of KKR's Health Care industry team; and Loporcaro.

GMR describes itself as the largest provider of emergency medical services in the United States, operating in approximately 1,400 counties and employing roughly 34,000 team members who support around 5.5 million patient encounters annually.

You May Also Be Interested In

• Virtus Investment Partners names Jack Boyce to its board
• BKV Corporation (BKV) files for 5.315M share offering by selling stockholders
• Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders